Study of MTX-463 for Idiopathic Pulmonary Fibrosis
Part of Lungs & breathing clinical trials.
This trial tests an experimental drug called MTX-463 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if targeting a protein called WISP1 can slow lung scarring and help you breathe better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 40 years old.
- You were diagnosed with IPF within the last 7 years.
- Your lung function (FVC) is at least 45% of normal and your ability to transfer oxygen (DLCO) is at least 25%.
- You are not on continuous oxygen and do not smoke or vape.
- If you take pirfenidone, nintedanib, or nerandomilast, your dose has been stable for at least 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental pill called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. The study aims to see if the drug can slow down the disease and improve breathing.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial tests a new medicine, ORJ-001, for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help slow the disease and improve breathing.
This study tests an experimental pill called SYH2059 for people with IPF, a condition that causes lung scarring and makes breathing harder. The goal is to see if the pill is safe and can help slow down the disease.
This trial tests an oral medication, ifetroban, to see if it can slow the progression of idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to improve breathing and lung function in patients with IPF.
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.